Molecular heterogeneity in intrahepatic cholangiocarcinoma.
Molecular heterogeneity in intrahepatic cholangiocarcinoma.
复制标题
DOI：
10.4254/wjh.v12.i12.1148
复制
发表时间：
2020-12-27
影响因子：
2.4
通讯作者：
Kang KJ
中科院分区：
文献类型：
--
作者：
Ahn KS;Kang KJ
肝内胆管细胞癌(ICCA)是一种异质性的原发性肝癌，目前靶向治疗的选择很少。在组织病理学上，iCCA根据形态(肿块形成型、导管周围浸润型和导管内生长型)和组织学(小管型和大管型)进行亚型划分。根据不同的组织病理类型，危险因素和预后等临床特征也不同。基因组图谱的最新发展揭示了几个预后不良和致癌途径激活的分子标记。探索每个患者的iCCA的分子特征是临床环境中的主要挑战，目前还没有有效的基于分子的靶向治疗。然而，最近的几项研究表明，基于分子的亚型具有相应的临床和病理特征。尽管亚型尚未被证实，但根据临床病理特征可以预测分子特征，这可能被用于临床和分子亚型综合和靶向治疗的更合理的方法。在这篇综述中，我们探索了iCCA的基因组图景，并试图在几个已发表的研究中找到临床病理和分子亚型的分子特征之间的相关性。这些结果揭示了未来的方向，可能会导致一种合理的靶向治疗方法。
Intrahepatic cholangiocarcinoma (iCCA) is a heterogeneous primary liver cancer, and currently there exist only a few options of targeted therapy. Histopathologically, iCCA is sub-classified according to morphology (mass forming type, periductal infiltrating type, and intraductal growing type) and histology (small duct type and large duct type). According to different histopathological types, clinical features such as risk factors and prognosis vary. Recent developments in genomic profiling have revealed several molecular markers for poor prognosis and activation of oncogenic pathways. Exploration of molecular characteristics of iCCA in each patient is a major challenge in a clinical setting, and there is no effective molecular-based targeted therapy. However, several recent studies suggested molecular-based subtypes with corresponding clinical and pathological features. Even though the subtypes have not yet been validated, it is possible that molecular features can be predicted based on clinicopathological characteristics and that this could be used for a more rational approach to integrative clinical and molecular subclassification and targeted therapy. In this review, we explored the genomic landscape of iCCA and attempted to find relevance between clinicopathologic and molecular features in molecular subtypes in several published studies. The results reveal future directions that may lead to a rational approach to the targeted therapy.
登录
查看更多内容
影响因子：
3.2
作者：
Xiaofang L;Kun T;Shaoping Y;Zaiqiu W;Hailong S
通讯作者：
Hailong S
影响因子：
--
作者：
Krasinskas, Alyssa M
通讯作者：
Krasinskas, Alyssa M
影响因子：
30.8
作者：
Jiao, Yuchen;Pawlik, Timothy M.;Anders, Robert A.;Selaru, Florin M.;Streppel, Mirte M.;Lucas, Donald J.;Niknafs, Noushin;Guthrie, Violeta Beleva;Maitra, Anirban;Argani, Pedram;Offerhaus, G. Johan A.;Roa, Juan Carlos;Roberts, Lewis R.;Gores, Gregory J.;Popescu, Irinel;Alexandrescu, Sorin T.;Dima, Simona;Fassan, Matteo;Simbolo, Michele;Mafficini, Andrea;Capelli, Paola;Lawlor, Rita T.;Ruzzenente, Andrea;Guglielmi, Alfredo;Tortora, Giampaolo;de Braud, Filippo;Scarpa, Aldo;Jarnagin, William;Klimstra, David;Karchin, Rachel;Velculescu, Victor E.;Hruban, Ralph H.;Vogelstein, Bert;Kinzler, Kenneth W.;Papadopoulos, Nickolas;Wood, Laura D.
通讯作者：
Wood, Laura D.
影响因子：
2.5
作者：
Borad MJ;Gores GJ;Roberts LR
通讯作者：
Roberts LR
影响因子：
3.7
作者：
Churi CR;Shroff R;Wang Y;Rashid A;Kang HC;Weatherly J;Zuo M;Zinner R;Hong D;Meric-Bernstam F;Janku F;Crane CH;Mishra L;Vauthey JN;Wolff RA;Mills G;Javle M
通讯作者：
Javle M